Keryx Biopharmaceuticals Announces Issuance of a New U.S.

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Keryx Biopharmaceuticals Announces Issuance of a New U.S. Patent for Auryxia(TM) (ferric citrate) Covering Orally Administrable Forms

NEW YORK, Dec. 4, 2014 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) announced today that the U.S. Patent and Trademark Office issued U.S. Patent No. 8,901,349 on December 2, 2014. The patent, which expires in 2024, claims a method of treating hyperphosphatemia comprising administering a therapeutically effective amount of an orally administrable form of ferric citrate to a subject, wherein the orally administrable form is prepared from a ferric citrate having a BET active surface area greater than about 16 sq. m/g. The patent also claims a broad category of orally administrable forms covering Auryxia, as well as other oral formulations that could be developed in the future.

On September 5, 2014, Auryxia™ (ferric citrate) was approved by the U.S. Food and Drug Administration for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

This newly issued patent further enhances the Company's key patent family, which includes U.S. Patent Nos. 7,767,851, 8,299,298, 8,338,642, 8,609,896, 8,754,257, 8,754,258, and 8,846,976 which expire in 2024, and U.S. Patent No. 8,093,423, which expires in 2026, before patent term extension. Each of these patents contains composition and method of use claims covering Auryxia.

Ron Bentsur, Chief Executive Officer of Keryx, commented, "The patent announced today represents our fourth U.S. patent issuance in 2014, and further fortifies the strength of our intellectual property position. This patent is significant in that it links orally administrable forms, including Auryxia, prepared from Keryx's unique API, having a surface area greater than about 16 sq. m/g." Mr. Bentsur added, "With the high surface area being a manufacturing specification for our API, we believe that the patent issued today provides another layer of substantial protection for Auryxia."

The Company continues to prosecute additional patent applications for Auryxia, which, if issued, would provide additional patent protection for Auryxia beyond 2030.  

In addition, the Company has filed its key patent families for Patent Term Extension, which, if granted, would add up to an additional 5 years to the patent protection for Auryxia. Following FDA approval, the FDA Substance Registration System adopted tetraferric tricitrate decahydrate as the name of the active ingredient approved for marketing by the FDA, to appropriately describe the Company's unique proprietary form of ferric citrate API. 

About Auryxia™ (ferric citrate)

Auryxia (ferric citrate) is an oral, absorbed, iron-based phosphate binder. In the United States, Auryxia was approved by the Food and Drug Administration (FDA) on September 5, 2014, for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis. Auryxia will be marketed in the U.S. by Keryx Biopharmaceuticals, Inc. Keryx plans to make Auryxia available to dialysis patients in the U.S. this year.

In January 2014, ferric citrate was approved for the treatment of patients with all stages of CKD in Japan, where it is being marketed as Riona® by Keryx's Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd.

In March 2014, Keryx filed a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA), seeking the approval of ferric citrate as a treatment of hyperphosphatemia in patients with CKD, including dialysis and non-dialysis dependent patients, and that application is currently under review.

For more information about Auryxia, visit www.Auryxia.com . For Full Prescribing Information for Auryxia, please visit http://keryx.com/wp-content/uploads/Auryxia_P...112014.pdf .

Auryxia (ferric citrate) Important Safety Information

Contraindication:  Patients with iron overload syndrome, e.g. hemochromatosis, should not take Auryxia (ferric citrate).

Iron Overload:  Iron absorption from Auryxia may lead to increased iron in storage sites. Iron parameters should be monitored prior to and while on Auryxia. Patients receiving IV iron may require a reduction in dose or discontinuation of IV iron therapy.

Accidental Overdose of Iron:  Accidental overdose of iron containing products is a leading cause of fatal poisoning in children under 6 years of age . Keep Auryxia away from children as it contains iron. Call a poison control center or your physician in case of an accidental overdose in a child.

Patients with Gastrointestinal Bleeding or Inflammation:  Safety has not been established for these patients.

Adverse Events: The most common adverse events with Auryxia were diarrhea (21%), nausea (11%), constipation (8%), vomiting (7%) and cough (6%) .  Gastrointestinal adverse reactions were the most common reason for discontinuing Auryxia (14%).

Auryxia contains iron and may cause dark stools, which is considered normal with oral medications containing iron.

Drug Interactions:  Doxycycline should be taken at least 1 hour before Auryxia. 

For Full Prescribing Information for Auryxia, please visit http://keryx.com/wp-content/uploads/Auryxia_P...112014.pdf .

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals, headquartered in New York, is focused on bringing innovative therapies to market for patients with renal disease. The Company's FDA-approved product, Auryxia, is indicated in the United States for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis. Keryx plans to commercially launch Auryxia in the U.S. at year end. For more information regarding Keryx, please visit www.keryx.com

Cautionary Statement

Some of the statements included in this press release particularly those regarding Keryx's additional patent applications that may cover Auryxia™ (ferric citrate), the results of clinical trials or the commercialization and subsequent clinical development of Auryxia (ferric citrate), may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially include the fact that the U.S. Patent and Trademark Office, or other similar foreign patent authorities, may not issue those patents; whether Auryxia will be successfully launched and marketed in the U.S.; whether Riona® will be successfully marketed by our Japanese partner, Japan Tobacco, Inc. and Torii Pharmaceutical Co., Ltd; the risk that the EMA may not concur with our interpretation of our Phase 3 study results, supportive data, conduct of the studies, or any other part of our MAA submission and could ultimately deny approval of the MAA; the risk that we may not be successful in the development of ferric citrate for the treatment of iron deficiency anemia in non-dialysis chronic kidney disease patients; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at  http://www.keryx.com . The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.

Amy Sullivan, Vice President - Corporate Development and Public Affairs Keryx Biopharmaceuticals, Inc. Tel: 617.466.3447; e-mail:

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Legato Frames Put Tiny AI to a Real-World Hearing Test

Updated Category News Views 100

A hearing aid that never enters the ear is a deceptively brutal product challenge. It has to hear speech through a mess of restaurant clatter, traffic, wind and ordinary human commotion; it has to run all day; and, crucially, it cannot look like a medical concession somebody reluctantly straps on. Legato Frames are aiming right at that knot, with femtoAI providing the...

Continue Reading
SecureSpace Plants a Fifth Flag in Miami Beach Storage

Updated Category News Views 90

A small box on Alton Road may carry outsized weight Miami Beach does not hand out cheap, easy real estate wins, which is why SecureSpace's opening at 633 Alton Road deserves a closer look than its modest footprint might suggest. The newly rebranded SecureSpace Miami Beach facility has 18,358 square feet of traditional storage and locker space spread across 536 units, plus...

Continue Reading
SanMar’s Lott Tops Promo Products Power 50 Again in 2026

Updated Category News Views 102

Branded hoodies and logo tumblers rarely make Wall Street’s pulse race, but the numbers behind them deserve a hard look. Jeremy Lott, president and CEO of SanMar, was named the most influential leader in the U.S. promotional-products business for the second consecutive year, taking No. 1 in the 2026 Counselor Power 50 ranking. Awards can be fluff. A repeat win beside...

Continue Reading
Kobo and CloudLibrary Make Library Ebooks Much Easier

Updated Category News Views 107

A tiny button can change whether a digital service gets used Borrowing an ebook ought not feel like assembling a radio in a dark garage, yet that is roughly where library reading has landed for plenty of people. OCLC's new CloudLibrary integration with Kobo strips out a particularly annoying step: U.S. and Canadian users can link accounts once, borrow a title, and have it...

Continue Reading
OREF Opens $185,000 Research Grant Funding Cycle Today

Updated Category News Views 88

A hundred grand aimed at better graft science is not pocket change, but it is not a finished clinical program either. That distinction matters with the Orthopaedic Research and Education Foundation's newly opened $185,000 grant cycle. This is targeted, early-to-midstream research support: the sort of money that can produce usable data, sharpen a clinical question, and...

Continue Reading
Bank of America AML Claims Put Controls Under Fire

Updated Category News Views 101

A $1.2 billion compliance bill has a way of making investors stop pretending controls are boring. Moore Law PLLC is urging Bank of America shareholders to contact the firm over allegations tied to the bank's anti-money-laundering and Bank Secrecy Act systems. The notice follows what it describes as landmark October 13, 2026 enforcement actions by the Treasury Department's...

Continue Reading
AES Clears FERC, Nearing Its December 2 Takeover Close

Updated Category News Views 112

One more regulatory gate just swung open for AES, and this deal is finally staring at the finish line instead of wandering through the usual approval swamp. The Federal Energy Regulatory Commission has issued its final order approving AES's acquisition by a consortium led by Global Infrastructure Partners, part of BlackRock, and EQT Infrastructure VI. The last major...

Continue Reading
ASUS Brings AI Infrastructure Choices to SC26 Floor

Updated Category News Views 257

Compute buyers are sick of being handed one locked box That is the nerve ASUS is pressing at SC26: enterprises want AI infrastructure that fits the job in front of them, not somebody else's tidy product roadmap. The company is pitching a full-stack “AI Factory” blueprint built across Intel, AMD and NVIDIA hardware, running from rack-scale systems and conventional...

Continue Reading
MassMedia's Two PRSA Wins Put Campaign Strategy in Focus

Updated Category News Views 100

A pair of trophies is nice; the underlying work matters more. MassMedia picked up two honors at the 2026 PRSA Las Vegas Valley Chapter Pinnacle Awards, presented October 28 at Siena Golf Club. One was a Pinnacle Award in Community Relations for its Safe Teen Driving work with Sam & Ash Injury Law. The other was an Award of Excellence in Reputation and Brand Management for...

Continue Reading
Alpha's Training Bet Reaches Into Aesthetic Care Networks

Updated Category News Views 186

Training is becoming part of the operating machine A certificate course is rarely the headline-grabber in healthcare services, yet this one deserves a closer look. Alpha Aesthetics Partners has launched Practice Aesthetics, a unified clinical education platform tied directly to its expanding network of medical aesthetics practices. This is not a public-market ticker...

Continue Reading

Top 5 Most Recently Viewed Articles

La-Z-Boy Faces Major Stock Decline After Weak Earnings Report

Updated Category News Views 264

La-Z-Boy Stock Experiences Significant Drop La-Z-Boy Incorporated (NYSE: LZB) witnessed a dramatic 23.55% decline in after-hours trading, with shares plummeting from $39.11 to $29.90. This downturn followed the release of disappointing first-quarter results that did not meet analysts' expectations, prompting concerns about operational challenges. Disappointing Earnings...

Continue Reading
CLEAR Secure, Inc. Reveals Impressive Q3 2025 Performance

Updated Category News Views 224

CLEAR Secure, Inc.'s Q3 2025 Financial Overview CLEAR Secure, Inc. (NYSE: YOU), the leader in secure identity technologies, has recently unveiled its financial highlights for the third quarter of the 2025 fiscal year. As an innovative firm at the forefront of identity verification, CLEAR continues to address the growing needs in the security sector amid increasing cyber...

Continue Reading
Ameren Corporation Celebrates 10 Years of Disability Inclusion

Updated Category News Views 62

Ameren Corporation Champions Disability Inclusion Ameren Corporation (NYSE: AEE) has made impressive advancements in promoting disability inclusion, scoring a perfect 100 on the Disability Equality Index for the tenth year running. This recognition highlights Ameren’s role as a leader in fostering an inclusive workplace that values diversity and actively supports...

Continue Reading
Labcorp Faces Lawsuit: Wiretapping Accusations Surface

Updated Category News Views 60

Labcorp's Legal Tangle Unveiled One minute you're on Labcorp's website searching for medical info, the next you're caught up in a class-action legal whirlwind. Legal drama is not on any patient’s checklist, but here we are, with Labcorp knee-deep in some serious allegations. The crux of the matter points to alleged wiretapping violations, with claims that Labcorp,...

Continue Reading
Advent's $2.5 Billion Acquisition of Sapiens: A New Era Looms

Updated Category News Views 203

Advent to Acquire Sapiens for $2.5 Billion Sapiens International Corporation N.V. (NASDAQ: SPNS), a leader in software solutions for the insurance sector, has seen its stock price soar following the exciting announcement that it will be acquired by global private equity firm Advent. The all-cash acquisition deal is valued at approximately $2.5 billion, indicating a...

Continue Reading